J&J Eprex Stability Improvements Planned In Response To Aplasia Incidence
Executive Summary
Johnson & Johnson will seek alternative stabilizers for its erythropoietin Eprex in response to reports of pure red cell aplasia following the removal of human serum albumin from the product formula
You may also be interested in...
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich
J&J Eprex “Best Handling Practices” Program Aims To Reduce PRCA Cases
Johnson & Johnson is instituting a best handling practices program for Eprex to reduce pure red cell aplasia associated with the product